The FDA has asked CytRx Corp. to halt a clinical trial of its Lou Gehrig's disease drug candidate, arimoclomol, and provide additional data on previous animal studies involving the treatment, the company said Tuesday. The Los Angeles-based biopharmaceutical firm stated that "arimoclomol has been shown to be safe and well-tolerated after being administered to about 185 study volunteers."

Related Summaries